Filtered By:
Cancer: Breast Cancer
Therapy: Radiation Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Status Epilepticus in Patients with SMART (P5.012)
CONCLUSIONS We describe three patients with SMART presenting with SE. Our cases raise the concern that SMART is not necessarily a migraine phenomenon but can be a form of focal SE associated with stroke-like symptoms. In patients with radiographic suspicion of SMART we suggest a low threshold for vEEG monitoring and aggressive anti-epileptic management.Disclosure: Dr. Fan has nothing to disclose. Dr. Gabriel has nothing to disclose. Dr. Gerard has nothing to disclose. Dr. Schuele has received personal compensation for activities with Sunovion and Eisai as a speaker.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Fan, P., Gabriel, H., Gerard, E., Schuele, S. Tags: Neuromuscular Disease and Epilepsy ePoster Session Source Type: research

PET/MRI Assessment of Acute Cardiac Inflammation 1 Month After Left-Sided Breast Cancer Radiation Therapy
Conclusion: Myocardial 18F-FDG uptake and functional MRI, including stroke volume and ECVs, were sensitive to changes at 1 mo after breast cancer RT, with findings suggesting an acute cardiac inflammatory response to RT.PMID:37192822 | DOI:10.2967/jnmt.122.264960
Source: Journal of Nuclear Medicine Technology - May 16, 2023 Category: Nuclear Medicine Authors: Oi Wai Chau Ali Islam Michael Lock Edward Yu Robert Dinniwell Brian Yaremko Muriel Brackstone William Pavlosky John Butler Heather Biernaski Chantelle Graf Gerald Wisenberg Frank S Prato Stewart Gaede Source Type: research

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research